BioCentury
ARTICLE | Clinical News

AT-406: Phase II started

June 13, 2016 7:00 AM UTC

Debiopharm began a double-blind Phase II trial of oral Debio 1143 plus carboplatin and paclitaxel. Debiopharm has exclusive, worldwide rights from Ascenta to develop and commercialize Debio 1143 (see ...